The in vitro activity of cefmenoxime (SCE-1365) was evaluated in a multiphased collaborative investigation. Over 7,500 consecutive clinical isolates were tested in five laboratories, and greater than 90%o of the following organisms were inhibited by cefmenoxime at the following concentrations: Enterobacteriaceae and non-enterococcal streptococci, 0.125 ,ug/ml; Staphylococcus aureus, <2.0 ,ug/ml; and nonfermenting gram-negative bacilli and Bacteroides fragilis group, s32 ug/ml. Both beta-lactamase-producing and -nonproducing Haemophilus influenzae and Neisseria gonorrhoeae were inhibited by cefmenoxime at s0.03 lig/ml. The spectrum of cefmenoxime was similar to that of other, newer cephalosporins, particularly cefotaxime. A pronounced inoculum effect was found with some species upon increasing inocula from 105 to 107 colony-forming units per ml, resulting in an approximate eightfold increase in minximum inhibitory concentrations. Cefmenoxime was bactericidal when tested with inocula of 105 colonyforming units per ml, and mean differences between the minimum inhibitory concentration and the miniimum lethal concentration were less than one log2 dilution. No significant hydrolysis of cefmenoxime by five different beta-lactamases was detectable, and cefmenoxime exhibited marked inhibition of type I beta-lactamases. Regression and error rate-bounded analyses of results of disk diffusion and reference broth microdilution susceptibility tests were performed on 421 bacterial isolates, and the following tentative zone size breakpoints are proposed: 222 mm, susceptible; c14 mm, resistant; and 15 to 21 mm, moderately susceptible (indeterminate). These data and cross-resistance studies with other newer cephalosporins indicate marked similarity of in vitro activity within this group of drugs, particularly between cefmenoxime, moxalactam, and cefotaxime. Any one of these could serve as the representative for the disk diffusion testing of this group of drugs if comparable minimum inhibitory concentration breakpoints were used for each drug.
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Cefmenoxime, formerly known as SCE-1365, over 7,500 recent clinical bacterial isolates, bacis a new cephalosporin structurally similar to tericidal activity against a select population of cefotaxime, differing from the latter by having a clinical isolates, effect of inoculum size on minimethyltetrazolthio group in the 3 position in-mum inhibitory concentrations (MICs), comparstead of an acetoxymethyl group. Cefmenoxime ison of in vitro activity of cefmenoxime with that by agar dilution at Northwestern Memorial Hospital, St. Francis Hospital, and St. Vincent Hospital utilizing the method recommended by the National Committee for Clinical Laboratory Standards (13) . These were conducted in Mueller-Hinton broth and agar (Difco) , respectively. The concentrations tested by both methods were: 0.125, 0.5, 1.0, 2.0, 4.0, 8.0, and 32.0 jg/ml.
The inoculum size for the microdilution broth method was approximately 5 x 105 colony-forming units per ml, and that for agar dilution was approximately 104 colony-forming units per spot. In other phases of the study, the MICs and minimum lethal concentrations were determined by microdilution broth methods as previously described (2) . Concentrations tested were serial twofold dilutions ranging from 256 to 0.008 jig/ ml. H. influenzae, Neisseria meningitidis, and N. gonorrhoeae strains were tested at the Centers for Disase Control by broth microdilution with MuellerHinton broth supplemented with 5% peptic digest of blood (Fildes reagent) (H. influenzae and N. meningitidis) and by agar dilution using proteose peptone agar no. 3 supplemented with 1% hemoglobin (BBL Microbiology Systems, Cockeysville, Md.) and 1% Kellogg supplement (23) (N. gonorrhoeae). These procedures have been previously described in detail (1, 18) .
The susceptibility of anaerobes was tested in WilkinsChalgren broth in microdilution trays incubated for 48 h anaerobically at 35°C in GasPak jars (BBL) as previously described (10) . The disk diffusion susceptibility testing was performed in accordance with standardized procedures (12) . Disk zone size interpretive criteria were determined by both regression analyses according to the formula of least squares as adopted for computer computation and the error ratebounded method of Metzler and DeHaan (11) .
The beta-lactamase hydrolysis rates of cefmenoxime and three other cephalosporins were determined by the spectrophotometric method described by Neu (14) at 255-to 273-nm wavelengths; The reaction mixtures contained 1.0 ml of 0.4 mM beta-lactam substrate in 0.05 M phosphate buffer (pH 7.0) at 37°C and 10 to 20 id of crude enzyme preparation. Decrease in optical density was recorded for 30 min, and the hydrolysis rates in micromoles per minute were converted to percentage rates relative to that of nitrocefin. Inhibition of nitrocefin (87/312) hydrolysis was measured by spectrophotometer at 37°C at a wavelength of 482 nm (15) . Reaction mixtures of nitrocefin and cefoxitin, and nitrocefin and cefotaxime were compared with nitrocefin and cefienoxime using crude enzyme preparation (inhibition studies).
RESULTS
Among the Enterobacteriaceae the susceptibility to cefmenoxime was much greater than susceptibility to cefamandole or cephalothin ( Tables 3  and 6 ).
The in vitro activity of cefmenoxime was compared with that of six other beta-lactams and gentamicin against 461 clinical strains contributed by the collaborating laboratories. This study showed marked similarity in the activity of cefmenoxime and the other third-generation cephalosporins, especially cefotaxime and moxalactam (Tables 4 through 6 (Table 4) . Moxalactam was 8 to 16 times less active than cefmenoxime and cefotaxine against P. mirabilis, but was more active than the other drugs against the indole-positive species. Cefmenoxime had lowest MIC9o values against S. marcescens and Citrobacter spp. It also had greater activity than gentamicin against all Enterobacteriaceae, except that gentamicin was slightly superior against Enterobacter spp. Cefoperazone had the best activity against P. aeruginosa (MIC9o, 8 ,ug/ml) and was slightly more active than gentamicin ( Table 5 ). The majority of P. aeruginosa was moderately susceptible (MIC, 16 to 32 ,g/ml) to cefmenoxime (78%), cefotaxime (76%), and moxalactam (66%). Other Pseudomonas spp. could be divided into two groups on the basis of their susceptibility to third-generation cephalosporins: P. acidovorans and P. stutzeri were extremely susceptible, and the remaining species were resistant (Table 5) . Cefotaxime was the most active cephalosporin against A. anitratus (MlCo0, 16 ,ug/ml), but was less active than the aminoglycoside, gentamicin (MIC9o, 4 ,ug/ml).
Cephalothin and cefamandole were fourfold more active against S. aureus than were thirdgeneration drugs, but a marked increase in MICs of all drugs tested was seen with methicillinresistant strains (Table 6 ). Enterococci were not susceptible to any of these drugs, but cefoperazone and cefamandole had the best activity (MIC90, 32,ug/ml). Cefmenoxime and cefotaxime exhibited the best activity against S. pneumoniae (MIC90, 0.06 and 0.12 ,ug/ml) and S. pyogenes (MlC9o, 0.03 Ag/ml). Moxalactam and cefoxitin were the least active of all cephalosporins tested against these two species (MICso, 1.0 and 2.0 ,ug/ml). N. meningitidis was extremely susceptible to all cephalosporins, with the third-generation drugs being somewhat more active (MIC9o, '0.008 yig/ml) than the earlier compounds (MICgo, 0.125 ,ug/ml).
When tested against 48 anaerobic isolates, cefmenoxime was intermediate among the other cephalosporins compared ( 1 ). This inhibitory spectrum was comparable to that of cefoxitin and cefotaximne.
The comparison of cefmenoxime MICs and zone sizes by disk diffusion testing is summarized in the scattergram in Fig. 2 (Fig. 3) . Furthermore, these categories segregated the organisms in the phase 1 clinical study (Fig. 3C ) in a fashion similar to that of the organisms in the regression analysis study (Fig. 3B) -thus demonstrating that the latter population was representative of current clinical isolates.
MICs of cefmenoxime, cefotaxime, and moxalactam against the same organisms used for the disk study showed no cross-resistance between cefmenoxime and cefotaxime and less than 1% cross-resistance with moxalactam by using the MIC breakpoints described above ( (Tables 1 through 6 ), as well as that of a previous report (20) , was considerably greater than that of cephalothin and cefamandole, and was remarkably similar to the activity reported for cefotaxime (1, 6, 7) and moxalactam (1, 3, 9, (19) , and because this MIC range for cefotaxime (6) and moxalactam (3) is considered indeterminate or moderately susceptible, the same is tentatively applied to cefmenoxime. That this category includes primarily P. aeruginosa and Acinetobacter sp. may be significant in clinical evaluations when the efficacy of the moderately s(iceptible category concept is tested.
Despite the considerable similarity of in vitro activity of these third-generation cephalosporins, preliminary pharmacological data in experimental animals suggest some potential advantages of cefmenoxime (19) . Although plasma levels of cefmenoxime and cefotaxime in animals were comparable, cefmenoxime tissue levels were significantly higher than those of cefotaxime, and the half-life in both plasma and tissue was greater for cefmenoxime (19) . Furthermore, cefmenoxime showed greater activity than ce- fotaxime in mice infected with several Enterobacteriaceae spp. (20) .
In view of the cefmenoxime structural similarity to cefotaxime at the 7 position, it is not surprising to find cefmenoxime to be comparably resistant to inactivation by bacterial beta-lactamases. When hydrolysis rates of cefmenoxime and other cephalosporins by several specific types of beta-lactamases were determined (Table 9), cefotaxime, as previously reported (22) , and cefmenoximne were virtually unaffected by the enzymes tested; the MICs for the corresponding enzyme-producing bacteria were significantly lower than those of cefamandole, which was much more susceptible to these enzymes.
Because of its high resistance to beta-lactamases, cefmenoxime was tested for its ability to inhibit beta-lactamase hydrolysis of a susceptible beta-lactam substrate, in this case, nitrocefin. The previously reported inhibitory spectrum of cefoxitin and cefotaxime (4, 5) was confirmed, and the spectrum of cefmenoxime was found to be essentially the same, i.e., all effectively inhibit Richmond and Sykes type I beta-lactamases, cefmenoxime showed slight inhibition of type III-b beta-lactamase compared with cefotaxime, which exhibited none. Since moxalactam has the same inhibitory spectrum as cefotaxime (5) , this is an additional property shared by the three third-generation drugs.
Resistance of cefmenoxime, cefotaxime, and moxalactam to the beta-lactamases of H. influenzae and N. gonorrhoeae is documented in Table 8 , which shows that the MICs for beta-A lactamase-positive and -negative strains are essentially the same. By contrast, cefamandole showed considerable susceptibility to the betalactamase of H. influenzae, but not to that of N. gonorrhoeae. The slightly greater resistance of beta-lactamase-negative N. gonorrhoeae to the cephalosporins shown in Table 8 is an interesting phenomenon partially explained by the inclusion in this group of seven strains exhibiting increased resistance to several other antibiotics (possible cell membrane permeability mutants). The activity of cefmenoxime was most comparable to that of cefotaxime or moxalactam, which were shown to be the most active cephalosporins among 13 beta-lactam antibiotics previously tested against both beta-lactamase-positive and -negative H. influenzae and N. gonorrhoeae (1).
The extremely low MICs of cefinenoxime and the third-generation cephalosporins against H. influenzae, N. meningitidis, and N. gonorrhoeae plus their resistance to the beta-lactamases produced by two of these species should qualify these drugs for clinical trials against infection due to these microbes.
The disk diffusion zone sizes versus MIC values of cefmenoxime (Fig. 2) 
